ADMA Biologics, Inc. (ADMA)
ADMA Stock Price Chart
Explore ADMA Biologics, Inc. interactive price chart. Choose custom timeframes to analyze ADMA price movements and trends.
ADMA Company Profile
Discover essential business fundamentals and corporate details for ADMA Biologics, Inc. (ADMA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Oct 2013
Employees
685.00
Website
https://www.admabiologics.comCEO
Adam S. Grossman
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
ADMA Financial Timeline
Browse a chronological timeline of ADMA Biologics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Mar 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is $0.16, while revenue estimate is $131.20M.
Earnings released on 6 Aug 2025
EPS came in at $0.15 surpassing the estimated $0.14 by +7.14%, while revenue for the quarter reached $121.98M , missing expectations by -6.38%.
Earnings released on 7 May 2025
EPS came in at $0.14 falling short of the estimated $0.16 by -12.50%, while revenue for the quarter reached $114.80M , missing expectations by -5.75%.
Earnings released on 3 Mar 2025
EPS came in at $0.14 falling short of the estimated $0.15 by -6.67%, while revenue for the quarter reached $117.55M , beating expectations by +8.19%.
Earnings released on 7 Nov 2024
EPS came in at $0.15 surpassing the estimated $0.13 by +15.38%, while revenue for the quarter reached $119.84M , beating expectations by +5.68%.
Earnings released on 8 Aug 2024
EPS came in at $0.13 surpassing the estimated $0.08 by +62.50%, while revenue for the quarter reached $107.19M , beating expectations by +24.05%.
Earnings released on 9 May 2024
EPS came in at $0.08 surpassing the estimated $0.06 by +33.33%, while revenue for the quarter reached $81.88M , beating expectations by +5.96%.
Earnings released on 28 Feb 2024
EPS came in at $0.04 surpassing the estimated -$0.01 by +420.00%, while revenue for the quarter reached $73.90M , beating expectations by +2.43%.
Earnings released on 8 Nov 2023
EPS came in at $0.01 surpassing the estimated $0.00 by +233.33%, while revenue for the quarter reached $67.27M , missing expectations by -1.77%.
Earnings released on 9 Aug 2023
EPS came in at -$0.02 falling short of the estimated -$0.02 by -19.98%, while revenue for the quarter reached $60.12M , beating expectations by +8.33%.
Earnings released on 10 May 2023
EPS came in at -$0.03 surpassing the estimated -$0.05 by +40.00%, while revenue for the quarter reached $56.91M , beating expectations by +6.56%.
Earnings released on 23 Mar 2023
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%, while revenue for the quarter reached $49.98M , beating expectations by +8.82%.
Earnings released on 9 Nov 2022
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $41.09M , beating expectations by +19.16%.
Earnings released on 10 Aug 2022
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%, while revenue for the quarter reached $33.91M , beating expectations by +6.58%.
Earnings released on 11 May 2022
EPS came in at -$0.10 falling short of the estimated -$0.08 by -25.00%, while revenue for the quarter reached $29.10M , beating expectations by +12.37%.
Earnings released on 24 Mar 2022
EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%, while revenue for the quarter reached $26.38M , beating expectations by +21.26%.
Earnings released on 10 Nov 2021
EPS came in at -$0.13 surpassing the estimated -$0.15 by +13.33%, while revenue for the quarter reached $20.68M , missing expectations by -11.76%.
Earnings released on 11 Aug 2021
EPS came in at -$0.15 matching the estimated -$0.15, while revenue for the quarter reached $17.83M , missing expectations by 0.00%.
Earnings released on 12 May 2021
EPS came in at -$0.16 surpassing the estimated -$0.17 by +5.88%, while revenue for the quarter reached $16.05M , beating expectations by +10.30%.
Earnings released on 25 Mar 2021
EPS came in at -$0.20 falling short of the estimated -$0.17 by -17.65%, while revenue for the quarter reached $13.96M .
Earnings released on 5 Nov 2020
EPS came in at -$0.19 surpassing the estimated -$0.21 by +9.52%, while revenue for the quarter reached $10.28M , meeting expectations.
ADMA Stock Performance
Access detailed ADMA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.